Skip to content
10-Q

Quarterly Report

SPYRE THERAPEUTICS, INC. SYRE

0001636282-25-000102

← back to feed
Filed
Nov 4, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 29, 2025 77.59M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$124.67M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $64.9M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $89.42M
Stockholders Equity Q3 2025 · Sep 30, 2025 $455.1M
Stockholders Equity Q3 2025 · Jun 30, 2025 $455.77M
Stockholders Equity Q3 2025 · Mar 31, 2025 $482.61M
Stockholders Equity Q3 2025 · Dec 31, 2024 $517.8M
Current Liabilities Q3 2025 · Sep 30, 2025 $46.27M
Current Liabilities Q3 2025 · Dec 31, 2024 $54.06M
Total Liabilities Q3 2025 · Sep 30, 2025 $49.5M
Total Liabilities Q3 2025 · Dec 31, 2024 $90.68M
Current Assets Q3 2025 · Sep 30, 2025 $504.6M
Current Assets Q3 2025 · Dec 31, 2024 $608.47M
Total Assets Q3 2025 · Sep 30, 2025 $504.6M
Total Assets Q3 2025 · Dec 31, 2024 $608.48M
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.24
Sga Expense Q3 2025 · Sep 30, 2025 $11.64M
Sga Expense Q3 2025 · Sep 30, 2025 $35.38M
Net Income Q3 2025 · Sep 30, 2025 −$11.18M
Net Income Q3 2025 · Sep 30, 2025 −$92.67M
Net Income Q3 2025 · Jun 30, 2025 −$36.72M
Net Income Q3 2025 · Mar 31, 2025 −$44.77M
Operating Income Q3 2025 · Sep 30, 2025 −$56.89M
Operating Income Q3 2025 · Sep 30, 2025 −$152.39M